Evidence map›Paper›PMID 29325447›Full record

ArticleThe American journal of psychiatry2018

Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults.

Nancy J Donovan, Joseph J Locascio, Gad A Marshall, Jennifer Gatchel, Bernard J Hanseeuw, Dorene M Rentz, Keith A Johnson, Reisa A Sperling, Harvard Aging Brain Study

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 2 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Preliminary Evidence That Cortical Amyloid Burden Predicts Poor Response to Antidepressant Medication Treatment in Cognitively Intact Individuals With Late-Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Older and wiser? The neural correlates of worry induction and reappraisal in older adults.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nancy J DonovanFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Joseph J LocascioFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Gad A MarshallFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Jennifer GatchelFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Bernard J HanseeuwFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Dorene M RentzFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Keith A JohnsonFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Reisa A SperlingFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Harvard Aging Brain StudyFrom the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston; the Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston; the Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass.; the Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neurosciences, Université Catholique de Louvain, Brussels; the Department of Psychiatry, the Department of Neurology, and the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Brigham and Women's Hospital · US

Funding

Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Hyun-Sik Yang · 2010 to 2026
$50.2M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Evolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6M
Characterizing the Evolution of Amyloid Deposition in Normal ElderlyR01AG037497 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSON, KEITH A. · 2010 to 2014
$3.2M
Fostering Research Mentorship & Training during Psychiatry Residency SupplementR25MH094612 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI FAVA, MAURIZIO, GREENFIELD, SHELLY F. · 2011 to 2022
$2.3M
Mentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4M
Depressive symptoms in the pathogenesis of preclinical Alzheimer's DiseaseK23AG058805 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GATCHEL, JENNIFER ROSE · 2018 to 2022
$992k
Loneliness and biomarkers of Alzheimer's disease in clinically normal elderlyR03AG045080 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DONOVAN, NANCY J. · 2013 to 2014
$177k
NIA NIH HHS K23 AG058805NIA NIH HHS K24 AG035007NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062421NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG027435NIA NIH HHS R01 AG037497NIA NIH HHS R03 AG045080NIMH NIH HHS R25 MH094612
6 · The paper itself

Abstract

objectiveTo understand the role of depressive symptoms in preclinical Alzheimer's disease, it is essential to define their temporal relationship to Alzheimer's proteinopathies in cognitively normal older adults. The study objective was to examine associations of brain amyloid beta and longitudinal measures of depression and depressive symptom clusters in a cognitively normal sample of older adults.

methodA total of 270 community-dwelling, cognitively normal elderly individuals underwent baseline Pittsburgh compound B (PiB) positron emission tomography (PET) measures of cortical aggregate amyloid beta and annual assessments with the 30-item Geriatric Depression Scale (GDS). The authors evaluated continuous PiB binding as a predictor of GDS score or GDS cluster, calculated as total scores and mean scores for three GDS item clusters (apathy-anhedonia, dysphoria, and anxiety-concentration), across time (1-5 years; mean=3.8 years) in separate mixed-effects models with backward elimination. Initial predictors included PiB binding, age, sex, Hollingshead score, American National Adult Reading Test (AMNART) score, apolipoprotein E ε4 status, depression history, and their interactions with time.

resultsHigher PiB binding predicted accelerated rates of increase in GDS score over time, adjusting for depression history. Higher PiB binding also predicted steeper rates of increase for anxiety-concentration scores, adjusting for depression history and the AMNART score-by-time interaction. In a post hoc model estimating anxiety scores without concentration disturbance items, the PiB binding-by-time interaction remained significant.

conclusionsHigher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals. Prior depression history was related to higher but not worsening symptom ratings. These results suggest a direct or indirect association of elevated amyloid beta levels with worsening anxious-depressive symptoms and support the hypothesis that emerging neuropsychiatric symptoms represent an early manifestation of preclinical Alzheimer's disease.

Indexed as

AgedAge FactorsAmyloid beta-PeptidesAnxietyBrainDepressionFemaleHumansLongitudinal StudiesMalePsychiatric Status Rating ScalesAmyloid beta-PeptidesDementia-Alzheimer-s DiseaseGeriatric PsychiatryMood Disorders-Unipolar

Identifiers

PMID29325447
PMCPMC5988933
OpenAlexW2782579702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.